Future of pharma R&D requires innovative dosage formulations, industry survey shows

A survey of 500 pharmaceutical industry influencers reveals that four out of five surveyed (82%) believe innovative dosage form technologies are required to meet the needs of today’s pharmaceutical research and development challenges.

Three-quarters (76%) are actively investigating strategies to improve pharmaceutical products by adding drug delivery functionality, such as patient-centric dosing, combination therapy and controlled release options. And, when asked to rank the top three key drivers of innovative dosage forms, patient safety was the top priority followed by combination therapies and controlled release.

“This survey provides critical insights into R&D needs in terms of dosage innovation and outsourcing decisions today and in the future,” said Nigel Walker, managing director of Nice Insight, a pharmaceutical industry market intelligence company. “This type of understanding is fundamental to interpreting the innovation likely to be required to meet evolving patient-centric dosage needs driven by healthcare trends,” he added.